Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Net Income towards Common Stockholders (2016 - 2025)

Dexcom (DXCM) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with $267.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 76.2% to $267.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $836.3 million, a 45.14% increase, with the full-year FY2025 number at $836.3 million, up 45.14% from a year prior.
  • Net Income towards Common Stockholders was $267.3 million for Q4 2025 at Dexcom, down from $283.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $283.8 million in Q3 2025 to a low of $48.6 million in Q1 2023.
  • A 5-year average of $128.9 million and a median of $110.6 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 86.26% in 2021, then surged 201.23% in 2024.
  • Dexcom's Net Income towards Common Stockholders stood at $56.5 million in 2021, then surged by 62.48% to $91.8 million in 2022, then soared by 179.19% to $256.3 million in 2023, then crashed by 40.81% to $151.7 million in 2024, then surged by 76.2% to $267.3 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Net Income towards Common Stockholders are $267.3 million (Q4 2025), $283.8 million (Q3 2025), and $179.8 million (Q2 2025).